Abstract: Objective This study aimed to investigate the cell-free and concentrated ascites reinfusion therapy (CFCART) for treatment of patients withdecompensated liver cirrhosis (DLC). Methods 140 patients with hepatitis B-induced DLC were enrolled in our hospitalbetween October 2018 and October 2020, and they were randomly divided into control and observation group, with 70 cases in each group. The patients in the control group wasintravenously given cefoperazone sodium and sulbactam sodium, and those in the observation group received CFCART therapy.The regimen lasted for two weeks. Serum urea nitrogen (BUN), creatinine (sCr), plasma renin activity (PRA) , endothelin-1(ET-1) and angiotensinogen II (Ang II),aldosterone (ALD), interleukin-6 (IL-6), IL-8 and IL-10, endotoxin (LPS) and nitric oxide (NO) levels were assayed. Results At the end of two week treatment, the total efficient rate in the observation group was 95.7%, significantly higher than 82.9%(P＜0.05) in the control; serumBUN and sCr levels in the observation were (5.7±1.6)mmol/L and (115.1±27.7)μmol/L, significantly lower than [(7.1±2.1)mmol/L and (132.6±31.3)μmol/L, P＜0.05] in the control; serum PRA, AngⅡ and ALD levels were (2.9±0.9)ng/mL/h, (290.5±64.3)ng/L and (258.1±74.2)pg/mL, all significantly lower than [(3.8±1.0)ng/mL/h, (320.9±75.4)ng/L and (276.5±68.4)pg/mL, respectively, P＜0.05] in the control; serum LPS and ET-1 levels were(0.07±0.01)EU/mL and (75.5±2.6)ng/L, significantly lower than [(0.10±0.03)EU/mL and (89.6±5.2)ng/L, P＜0.05], while serum NO level was(69.4±4.3)μmol/L, significantly higher than [(55.7±3.6)μmol/L, P＜0.05] in the control group. Conclusion The CFCART therapy in dealing with patients with DLC could effectively improve kidney functions, which might be related to the inhibition of renin angiotensin aldosterone system.

Key words: Liver cirrhosis, Ascites concentration and reinfusion, Cefoperazone/sulbactam, Renin angiotensin aldosterone system, Therapy